IO Biotech Announces 2023 First-Quarter Results
11 mai 2023 16h05 HE
|
IO Biotech
The company expects to enroll 225 patients in its Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma by mid-2023 and to fully enroll the trial by the end of 2023.The Phase 3 trial protocol...
IO Biotech Announces 2022 Fourth-Quarter and Year-End Results
14 mars 2023 16h11 HE
|
IO Biotech
Enrollment in the company’s Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully...
IO Biotech to Participate in March 2023 Investor Conferences
22 févr. 2023 07h00 HE
|
IO Biotech
NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® vaccine...
IO Biotech Announces Appointment of Devin Smith as General Counsel
23 janv. 2023 08h00 HE
|
IO Biotech
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine...
IO Biotech Provides Business Update
09 janv. 2023 07h05 HE
|
IO Biotech
Independent data monitoring committee recommends that the company’s Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients continue without any...
IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
09 nov. 2022 16h07 HE
|
IO Biotech
- Preclinical data showing the rationale for two new pipeline candidates targeting the immunosuppressive effects of Arginase-1 (ARG1) and Transforming Growth Factor Beta 1 (TGFb1) were presented in...
IO Biotech Announces Third Quarter Results for 2022
09 nov. 2022 16h05 HE
|
IO Biotech
Clinical trial site activation, a leading indicator of patient enrollment, has accelerated in the past three months in the company’s global Phase 3 combination trial of IO102-IO103 and KEYTRUDA®...
IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors
03 nov. 2022 08h00 HE
|
IO Biotech
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech to Participate in the Jefferies London Healthcare Conference
31 oct. 2022 08h00 HE
|
IO Biotech
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Appointment of New Chief Financial Officer
13 oct. 2022 16h05 HE
|
IO Biotech
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...